Liubing Li
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Epidemiology 26
- Inflammatory Myopathies and Dermatomyositis 13
- Rheumatology 25
- Systemic Lupus Erythematosus Research 15
- Eosinophilic Disorders and Syndromes 6
- Co-authors
- Yongzhe Li (41 shared papers)Chenxi Liu (24 shared papers)Yangyun Wang (10 shared papers)Linlin Cheng (12 shared papers)Songxin Yan (11 shared papers)Haizhen Chen (8 shared papers)Haolong Li (5 shared papers)Yong Wang (6 shared papers)
- Journals
- Clinical Rheumatology (8 papers)Scientific Reports (3 papers)Infection and Drug Resistance (3 papers)Oncotarget (3 papers)Medicine (3 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Liubing Li
84 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 117
- Biomaterials 218
- Infectious Diseases 307
- Molecular Medicine 80
- Rheumatology 218
- Biomedical Engineering 414
Countries citing papers authored by Liubing Li
This map shows the geographic impact of Liubing Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liubing Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liubing Li more than expected).
Fields of papers citing papers by Liubing Li
This network shows the impact of papers produced by Liubing Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liubing Li. The network helps show where Liubing Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Liubing Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 277 | |
| 2 | 2020 | 245 | |
| 3 | 2015 | 100 | |
| 4 | 2022 | 81 | |
| 5 | 2016 | 54 | |
| 6 | 2021 | 50 | |
| 7 | 2018 | 45 | |
| 8 | 2015 | 45 | |
| 9 | 2015 | 41 | |
| 10 | 2023 | 34 | |
| 11 | 2016 | 33 | |
| 12 | 2018 | 32 | |
| 13 | 2017 | 31 | |
| 14 | 2017 | 30 | |
| 15 | 2019 | 25 | |
| 16 | 2016 | 22 | |
| 17 | 2011 | 22 | |
| 18 | 2016 | 22 | |
| 19 | 2022 | 17 | |
| 20 | 2018 | 17 |
About Liubing Li
Liubing Li is a scholar working on Epidemiology, Rheumatology, Molecular Biology, Immunology and Pulmonary and Respiratory Medicine, having authored 87 papers that have together received 1.6k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (15 papers), Inflammatory Myopathies and Dermatomyositis (13 papers), Vasculitis and related conditions (7 papers), Knee injuries and reconstruction techniques (6 papers), Nanoplatforms for cancer theranostics (6 papers), Eosinophilic Disorders and Syndromes (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Systemic Sclerosis and Related Diseases (6 papers). The work is most often cited by research in Biomaterials (218 citations), Infectious Diseases (307 citations), Molecular Medicine (80 citations), Rheumatology (218 citations) and Biomedical Engineering (414 citations). Liubing Li has collaborated with scholars based in China and United States. Frequent co-authors include Yongzhe Li, Chenxi Liu, Yangyun Wang, Linlin Cheng, Songxin Yan, Haizhen Chen, Haolong Li, Yong Wang, Leshuai W. Zhang and Liqin Shen. Their work appears in journals such as Clinical Rheumatology, Scientific Reports, Infection and Drug Resistance, Oncotarget and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.